|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
BIND Biosciences, Inc. Granted Five U.S. Patents for its Medicinal Nanoengineering® Platform and Lead Drug Candidate, BIND-014
1/8/2013 9:40:17 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that the United States Patent and Trademark Office (USPTO) has recently granted five U.S. patents to the Company, bringing the total patents issued to the Company in 2012 to ten. These patents cover BIND-014, the Company’s lead Accurin product candidate in Phase 1 clinical development for the treatment of solid tumor cancers, and BIND’s Medicinal Nanoengineering® platform, which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.
|
|
|
|
|
|
|
|
|
|
|